top of page
RESEARCH
12 | Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis BUndergoing Antiviral Treatments in a Real-World Setting |
11 | Systematic Review of Individual-Level Simulation in Cost-Effectiveness Analysis of Antiviral Treatments in Patients with Hepatitis B |
10 | Development of Scenarios By Health State to Measure the Quality of Life of Spinal Muscular Atrophy in the General Population |
9 | Use of the Narcotics Information Management System (NIMS) Data for Regulatory Science: Focusing on Methylphenidate Prescription |
8 | Application of External Comparators Using Rea-world Data in Healthcare Technology Assessment: Focusing on a Historical Cohort Example |
7 | Critical review of cost-effectiveness studies of nusinersen in patients with spinal muscular atrophy |
6 | Long-Term Cost-Effectiveness of Fractional Flow Reserve in Stable and Unstable Angina Patients |
5 | Differences in the Use of Medications for Treated ADHD patients between children and adults from Real-World Data in Korea |
4 | Assessment of adverse events following influenza vaccination using real-world big data |
3 | Nationwide prescription trends of methylphenidate in Korea using the Narcotics Information Management System data |
2 | Imbalanced Data Bias in Logistic Regression to Estimate Treatment Effects: Results from a Virtual Patient Cohort Simulation |
1 | Cost-effectiveness analysis for expanding the coverage of antiviral drugs in patients with untreated minimally active chronic hepatitis B |
bottom of page